Clinical Trial Update: A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study evaluating voxelotor (Oxbryta) in sickle cell disease patients at highest risk for progressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Sickle Cell Nephropathy

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Sickle Cell Disease, Sickle Cell Nephropathy | Phase 1, Phase 2 | Status: TERMINATED